Amgen (AMGN) Q1 2024 Earnings
AMGN·Reported May 2, 2024·After market close
Amgen reported Q1 2024 revenue of $7.4B, missed analyst consensus of $7.5B by $4.6M. Diluted EPS came in at $3.96, beat the $3.88 consensus by $0.08. Amgen reports across 1 business segment, led by Human Therapeutics.
Revenue
$7.4Bmissed by $4.6M
Consensus: $7.5BDiluted EPS
$3.96beat by $0.08
Consensus: $3.88
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Amgen's Q1 2024 earnings report.
Amgen (AMGN) reported Q1 2024 earnings on May 2, 2024 after market close.
Amgen reported revenue of $7.4B and diluted EPS of $3.96 for Q1 2024.
Revenue missed the consensus estimate of $7.5B by $4.6M. EPS beat the consensus estimate of $3.88 by $0.08.
You can read the 10-Q periodic report (0000318154-24-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.